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Triggering receptor expressed on myeloid cells-2 (TREM2) is a cell surface receptor on 
macrophages and microglia that senses and responds to disease associated signals to regulate 
the phenotype of these innate immune cells. The TREM2 signaling pathway has been 
implicated in a variety of diseases ranging from neurodegeneration in the central nervous 
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system to metabolic disease in the periphery. We report here that TREM2 is a thyroid hormone 
regulated gene and its expression in macrophages and microglia is stimulated by thyroid 
hormone.  Both endogenous thyroid hormone and sobetirome, a synthetic thyroid hormone 
agonist drug, suppress pro-inflammatory cytokine production from myeloid cells including 
macrophages that have been treated with the SARS-CoV-2 spike protein which produces a 
strong, pro-inflammatory phenotype. Thyroid hormone agonism was also found to induce 
phagocytic behavior in microglia, a phenotype consistent with activation of the TREM2 pathway.  
The thyroid hormone antagonist NH-3 blocks the anti-inflammatory effects of thyroid hormone 
agonists and suppresses microglia phagocytosis. Finally, in a murine experimental autoimmune 
encephalomyelitis (EAE) multiple sclerosis model, treatment with Sob-AM2, a CNS-penetrating 
sobetirome prodrug, results in increased Trem2 expression in disease lesion resident myeloid 
cells which correlates with therapeutic benefit in the EAE clinical score and reduced damage to 
myelin. Our findings represent the first report of endocrine regulation of TREM2 and provide a 
unique opportunity to drug the TREM2 signaling pathway with orally active small molecule 
therapeutic agents. 
Introduction 
Thyroid hormone (TH) provides essential regulation of many critical processes in 
vertebrate biology.1 Thyroxine (T4) is the predominant form of TH produced in and secreted 
from the thyroid gland, but its deiodinated metabolite 3,5,3’-triiodothyronine (T3) is the active 
form of TH that binds thyroid hormone receptors (TR) with high affinity. TRs bind to regulatory 
DNA sequences called thyroid hormone response elements (TRE) in the promoter regions of 
TH regulated genes, and T3 binding to TR in the cell nucleus activates TR to either stimulate or 
suppress transcription of these genes. Through such regulation of target genes TH action plays 
an important developmental role in the central nervous system (CNS) and periphery, as well as 
regulation of metabolism and homeostasis in many organs and cell types in the periphery. It is 
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known that TH exerts effects on the immune system, in particular the innate immune cells, such 
as TR-expressing tissue-resident macrophages and microglia in the CNS; however, the 
mechanistic basis of TH-dependent effects on innate immunity is not well understood.2 
Triggering receptor expressed on myeloid cells (TREM2) has emerged recently as a 
major regulator of the innate immune response and an important new therapeutic target 
connected to a number of diseases in the CNS and periphery.3 Expressed as a cell surface 
protein on macrophages and microglia, activation of TREM2 initiates a signal transduction 
cascade that triggers a switch in these cells away from a pro-inflammatory phenotype to an anti-
inflammatory, phagocytic, restorative phenotype. Homozygous loss of function mutations in 
TREM2, or DAP12, a molecule that interacts with TREM2 to facilitate TREM2 signaling, causes 
Nasu-Hakola disease, a rare inborn error resulting in premature dementia, loss of myelin, and 
bone abnormalities.4 In addition, heterozygous TREM2 missense variants have been shown to 
be risk factors for common neurodegenerative diseases such as Alzheimer’s disease (AD), 
frontotemporal dementia, Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS).3, 5-6 
In the periphery,TREM2 expressed on circulating monocytes and tissue-resident macrophages 
has been implicated to play a beneficial role in controlling/resolving obesity/excess adiposity,7 
non-alcoholic steatohepatitis (NASH),8 and hepatocellular carcinoma.9 In most of these 
diseases it appears that activation of the TREM2 pathway by increasing surface expression of 
TREM2 on macrophages and/or microglia and/or activating TREM2 with an agonist ligand is 
likely to be therapeutically beneficial. One of the main obstacles to targeting TREM2 for 
therapeutic benefit is that it falls into the category of “undruggable” or at least difficult to drug 
targets. This results from the nature of the ligands that bind to and activate TREM2. The general 
consensus is that TREM2 does not bind to a single, discrete ligand, but instead binds and is 
activated by various proteins, lipids, and other debris arising from damaged cells.10  
Here we report the discovery that Trem2 is a positively regulated thyroid hormone target 
gene. TREM2 expression and signaling through the TREM2 pathway is increased both in vitro 
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and in vivo by treatment with T3, or the peripheral and CNS-penetrating thyromimetic agents 
sobetirome and Sob-AM2, respectively. This discovery effectively renders TREM2 “druggable” 
by systemically dosed small molecules with sufficient drug-like properties for targeting the 
TREM2 pathway in either the CNS or periphery. 
Results 
Our interest in TREM2 was initiated from reports that microglia and macrophages 
increased phagocytic capacity upon treatment with the retinoid X receptor (RXR) agonist 
bexarotene,11 and treatment of TREM2-expressing myeloid lineage cells with other nuclear 
receptor agonists including PPAR and LXR also stimulated phagocytosis.12 Based on 
comprehensive genome-wide studies in mice, it has been reported that the Trem2 gene is 
regulated by an RXR-dependent enhancer.13 Because a major biological function of RXR is to 
form heterodimers at positively-regulated response elements with thyroid hormone receptor 
(TR) and other members of nuclear receptor family including PPAR and LXR, we examined this 
enhancer from murine macrophages. We found the following sequence embedded in the 
putative RXR enhancer of Trem2—AGGGAG-GTTA-AGGTCA—which is a canonical DR4 
thyroid hormone response element (TRE) (Fig.1).  The AGGGAG is a consensus half-site for 
binding RXR, and AGGTCA is a consensus half-site for TR; the four intervening nucleotides 
(GTTA) make this a positively regulated DR4 TRE which should increase TREM2 expression 
upon binding thyroid hormone agonists to TR (Fig. 1a).  
We verified that TREM2 expression is indeed positively regulated by thyroid hormone in 
both murine (Fig. 2a) and human (Fig. 2b) microglia, murine macrophages (Fig. 2c), and in 
mouse brain homogenate (Fig. 2d). Sobetirome is a synthetic T3 agonist drug that has a larger 
therapeutic index (TI) than T3, and Sob-AM2 is a prodrug of sobetirome that greatly facilitates 
delivery of sobetirome to the CNS from a systemic dose (Fig. 1b).14-16 We examined the ability 
of these agents to drive Trem2 expression and found that sobetirome stimulates Trem2 
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expression in mouse and human microglia (Fig. 2a,b), and hypothyroid mice treated with Sob-
AM2 (i.p.) had increased Trem2 expressed in brain compared to hypothyroid control (Fig. 2d). 
To verify the involvement of TR in the observed TREM2 regulation by TH, the TR antagonist 
NH-3 (Fig. 1b) was employed in combination with T3.17 NH-3 was not only found to block T3 
induction of Trem2 expression in murine microglia, but to suppress Trem2 expression 
significantly below the basal level observed in vehicle treated cells (Fig. 2a). As mentioned 
above, activation of the TREM2 signaling pathway induces both a pro-phagocytic and an anti-
inflammatory response in monocytes and macrophages. We found that expression of the 
phagocytic marker Cd68 was increased in microglia by treatment with either T3 or sobetirome, 
and the T3 effect was blocked by the TR antagonist NH-3 (Fig. 2e).  In addition, expression of 
the pro-inflammatory cytokine interleukin-1β (IL-1β) was significantly decreased by T3 and 
sobetirome in mouse primary microglia (Fig. 2f).  
We next examined thyroid hormone regulated gene expression of the pro-inflammatory 
cytokine interleukin-6 (IL-6) to test the breadth of anti-inflammatory effects that would expected 
by thyromimetic stimulation of the TREM2 pathway.  We tested whether IL-6 expression 
stimulated from an inflammatory challenge in macrophages could be suppressed by 
thyromimetic stimulation of TREM2 expression. (Fig. 3). It has been shown that macrophages 
incubated with coronavirus (SARS-CoV and SARS-CoV-2) spike S1 protein induce the 
production of pro-inflammatory cytokines including IL-6.18-21 RAW 264.7 cells stimulated with 
SARS-CoV-2 spike S1 protein induced a surge in IL-6 expression compared to unstimulated 
cells, and this response was significantly attenuated upon treatment with T3 (Fig. 3a). T3 
treatment also significantly suppressed Il6 (Fig. 3b) and Il1b expression (Fig. 3c) in mouse 
primary lung macrophages stimulated with S1 protein. Concomitant with suppression of these 
pro-inflammatory cytokines, we observed stimulation of Trem2 expression by T3 in primary lung 
macrophages (Fig. 3d).  
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The finding that TH agonists upregulate both TREM2 and CD68 expression predicts that 
phagocytosis will be stimulated by these drugs. This prompted us to directly examine 
phagocytosis, which is an established consequence of TREM2 signaling pathway activation in 
myeloid lineage cells. In order to ascertain the phagocytic response upon drug treatment, 
mouse primary microglia were cultured on glass coverslips and treated with drugs in the 
presence of fluorescent beads used as a phagocytosis substrate that can be monitored and 
quantified by fluorescence microscopy.22 Cellular bead uptake was evaluated via 3D volume 
visualization down orthogonal axes to confirm complete entrapment as shown in Fig. 4g. 
Microscopy of cells stained for CD11b microglial expression showed that T3 and sobetirome 
treatment significantly increased phagocytosis compared to vehicle control as judged by the 
number of beads engulfed by the microglia (Fig. 4a-c’). Conversely, the T3 antagonist NH-3 
treatment was found to suppress phagocytic uptake of beads compared to vehicle-treated 
control (Fig. 4d,d’). Quantification of these microscopy data demonstrate that TH agonists 
stimulate, while TH antagonists block, phagocytosis in microglia (Fig. 4h). These results 
corroborate existing literature reporting augmented phagocytosis upon T3 treatment in 
macrophages.23   
We have shown previously that CNS-penetrating thyromimetics stimulate myelin repair 
in different murine models of demyelination.24 One such model is experimental autoimmune 
encephalomyelitis (EAE), which is a demyelination model stimulated by an autoimmune attack 
that has parallels to the human disease multiple sclerosis.  The autoimmune insult in EAE 
produces demyelination and axonal degeneration, particularly in the lumbar spinal cord region in 
mice.  We have shown that in mice with EAE, T3, sobetirome, and Sob-AM2 treatment reduces 
clinical disease scores and demyelination and axonal degeneration within the spinal cord.25 
Thus, the question arises as to whether this results in part from thyromimetic stimulation of the 
TREM2 signaling pathway in microglia and macrophages to induce phagocytosis of myelin 
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debris, which is known to be a prerequisite to myelin repair.26 EAE was induced in C57Bl/6 mice 
within a 21-day treatment regimen, where mice were administered once daily injections of 
vehicle, T3, or Sob-AM2 starting 7 days after immunization before disease onset and continuing 
until day 21 when euthanasia and tissue collection occurred. Spinal cord sections co-stained 
with DAPI and TREM2 antibodies in the dorsal white matter of the lumbar section of spinal 
cords were analyzed for TREM2 content (Fig. 5a-c). Compared to vehicle, TREM2 protein 
expression was increased approximately four-fold and three-fold by T3 and Sob-AM2 treatment, 
respectively (Fig. 5d). Immunohistochemical analysis of this same spinal cord region showed 
that the population of CD11b positive cells, which correspond to microglia and/or macrophages, 
were not statistically different between Sob-AM2 treated mice and vehicle (see Supplementary 
Fig. S6).25 This indicates that the increase in TREM2 staining was not a result of increased 
myeloid cells in the spinal cord lesions. This increase in TREM2 protein expression observed by 
immunohistochemical analysis of spinal cord sections was confirmed by ELISA of spinal cord 
homogenate from unprocessed/unstained samples of the same groups (Fig. 5e). Improvement 
in EAE clinical scores (Fig. 5f) was observed in the mouse cohorts which were stained and 
correlates with augmented TREM2 expression.  
Discussion 
 TREM2 has emerged as a central node in the innate immune response governing 
whether myeloid lineage macrophages and microglia have a pro-inflammatory or anti-
inflammatory, restorative, healing phenotype in response to pathological insults.  Here we report 
the discovery that TREM2 is a direct target for regulation by thyroid hormone. The promoter 
region of the TREM2 gene contains a consensus DR4-TRE which presents binding sites for the 
RXR-TR heterodimer that stimulates TREM2 expression in response to thyroid hormone 
agonists. We found that TREM2 expression was increased in both microglia and macrophages 
by addition of either T3 or the synthetic T3 analog sobetirome, and this T3 agonist induction of 
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TREM2 was blocked by the T3 antagonist NH-3. We also found that the proinflammatory 
cytokines IL-1β and IL-6 that are downregulated by induction of the TREM2 pathway were 
downregulated by T3 and sobetirome in microglia and macrophages that have been stimulated 
with the pro-inflammatory SARS-CoV-2 spike protein.  Activation of the TREM2 pathway 
induces phagocytosis in these myeloid cells and T3 and sobetirome were found to induce 
phagocytosis in microglia whereas the T3 antagonist NH-3 blocked phagocytosis. Finally using 
the murine EAE model we showed that demyelinated regions of the spinal cord from mice 
treated with Sob-AM2, a CNS-penetrating prodrug of sobetirome, contained more TREM2 
positive cells than control mice. Importantly, mice treated with Sob-AM2 had reduced clinical 
impairment, demyelination and axonal degeneration, suggesting that thyromimetic stimulation of 
TREM2 could result in protection in the inflammatory disease EAE. To our knowledge, ours is 
the first report that TREM2, and by extension the TREM2 pathway, is subject to endocrine 
regulation. 
 It has become increasingly apparent that thyroid hormone action plays a role in 
modulating innate immunity.27 Control of intracellular T3 levels in macrophages has been shown 
to be critical for these cells to respond appropriately to inflammatory signals.28-29 In addition, 
thyroid status dictates the degree to which rats respond to an inflammatory insult in which 
hypothyroidism induces increased pro-inflammatory cytokine production while hyperthyroidism 
inhibits this response.30 Administration of T3 blocks NLRP3 inflammasome activation, which 
depends upon NF-kB activation and results in IL-1β production and release, in different models 
of liver injury.31-32 In a model of kidney injury, deletion of the TRα isoforms result in increased 
injury, and isolated macrophages lacking TRα produce excessive levels of IL-1β compared to 
WT control.33 In addition to these examples of driving the transition to an anti-inflammatory 
phenotype in macrophages, TH has also been shown promote phagocytosis in macrophages,23 
a response that we recapitulated here in microglia treated with T3.  Collectively, these myeloid 
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cell observations from both in vitro and in vivo experiments can be explained by thyroid 
hormone activation of the TREM2 pathway. 
 The sequelae of Nasu-Hakola disease provides genetic evidence that functional TREM2 
and its signaling pathway in myeloid cells is essential for a normal, disease-free human 
lifespan.4 Over the past few years it has become increasingly apparent that the biology of the 
TREM2 signaling pathway is more involved in responding to pathological conditions as opposed 
to homeostatic physiology.3 For example, TREM2 is known to play a major role in a disparate 
collection of diseases including neurodegenerative diseases,5, 34 metabolic diseases,7-8 
infectious diseases,35-36 cancer,9, 37-39 and stroke.40 Heterozygous missense mutations in TREM2 
are associated with strong increased risk of developing late onset Alzheimer’s disease (AD),41-42 
and increased cerebrospinal fluid (CSF) levels of the soluble extracellular domain of TREM2 
(sTREM2) has been shown to correlate with less disease severity in AD.43 This suggests that 
increased expression of TREM2 and/or increased signaling through the TREM2 pathway in 
microglia may be therapeutically beneficial in AD. It has also been known for some time that 
decreased thyroid hormone action in the CNS is detrimental while increased thyroid hormone 
action in the CNS correlates with clinical benefit in AD and other diseases of cognitive 
impairment.44-50 Our finding that TREM2 is a thyroid hormone regulated gene whose expression 
is increased by T3 acting on TR in microglia suggests a mechanistic connection between 
elevated levels of T3 in the CNS and clinical benefit in AD and related disorders. The beneficial 
effect of increased T3 in the brain may in part relate to increased stimulation of TREM2 
expression in microglia and increased activity through the TREM2 pathway.  
Another neurodegenerative disease that TREM2 appears associated with is multiple 
sclerosis (MS), an autoimmune disease that causes inflammatory demyelination and 
degeneration of axons in the CNS. Similar to AD, sTREM2 levels in the CSF are elevated in 
both relapsing remitting and primary progressive MS patients compared to CSF from patients 
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with non-inflammatory neurological disease.51 In addition, TREM2-expressing myeloid cells 
have been detected in CSF and in demyelinating lesions upon autopsy from MS subjects.51 
Macrophages and microglia release proinflammatory cytokines and probably contribute to 
demyelination and axonal degeneration in MS. In addition, microglia and macrophages play an 
important role in clearing myelin debris in demyelinating lesions that occur in MS via 
phagocytosis, which is a prerequisite to forming new myelin from mature oligodendrocytes.26 
We have shown previously that the thyroid hormone receptor agonists sobetirome and Sob-
AM2 promote remyelination in murine gliatoxin and genetic models of demyelination, and have 
further shown that like thyroid hormone, these agents stimulate oligodendrogenesis in vitro and 
in vivo.24 Our findings presented here that sobetirome induces TREM2 expression through TR 
activation in myeloid cells which stimulates phagocytosis in microglia constitutes a second 
beneficial mechanism of action in addition to oligodendrogenesis for thyroid hormone agonists 
as myelin repair agents. 
This leads to the question of how the TREM2 pathway can be best engaged by drugs for 
therapeutic benefit. One approach would be to develop TREM2 agonists or antagonists that 
engage TREM2 directly to activate or block downstream signaling. A problem with this approach 
is that endogenous ligands for TREM2 appear to be a heterogenous collection of molecules 
associated with cell damage as opposed to a discrete metabolite or protein which is more 
amenable to drug discovery approaches. Some success has been reported with anti-TREM2 
antibodies that act as agonists upon TREM2 binding,52-53 but the challenge with biologic agents 
such as antibodies is their intrinsic limits on distribution to different tissues and compartments 
affected by disease. For example, distribution from blood to the CNS is difficult with antibodies, 
and many of the diseases that would benefit from TREM2 engagement are localized in the 
CNS. Our findings that TREM2 is a thyroid hormone regulated gene and that TREM2 
expression and the TREM2 pathway can be activated or blocked by T3 agonists or antagonists 
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opens the door to a therapeutic approach based on orally active small molecules. A number of 
studies have demonstrated that increased expression of TREM2 in microglia and/or 
macrophages alone serves to activate the TREM2 signaling pathway,43, 54-56 and this is 
consistent with our observations that T3 agonists increase TREM2 expression and activate the 
TREM2 pathway, whereas the T3 antagonist NH-3 blocks TREM2 expression and downstream 
signaling such as that involved in phagocytosis. The T3 agonist sobetirome would be 
representative of a drug candidate designed to stimulate the TREM2 pathway in the periphery 
for therapeutic benefit. Sobetirome therapy would be indicated, for example, for diseases of the 
liver that may benefit from activation of TREM2 such as NASH,8 immune-mediated damage 
following liver injury,57 and hepatocellular carcinoma.9 Alternatively, for peripheral diseases that 
may benefit from temporary blockade of the TREM2 pathway such as early in respiratory viral 
infection35 and certain cancers in which a robust immune response would be beneficial,38-39 the 
T3 antagonist NH-3 could be employed.  However, during later stages of viral infection when 
cytokine storm can present, as can occur in COVID-19 critical illness, activation of the TREM2 
pathway by sobetirome to drive macrophages to transition to an anti-inflammatory, resolving 
phenotype would be more appropriate for therapeutic benefit.58-59 The CNS-penetrating 
sobetirome prodrug Sob-AM2 would be the appropriate agent for AD, MS, and other 
neurodegenerative diseases for which therapeutic benefit would potentially come from TREM2 
activation in the CNS while minimizing TREM2 activation and other thyromimetic activity in the 
periphery. And finally, should there be an application for blocking TREM2 activation in the CNS, 
the N-methyl amide prodrug of antagonist NH-3 provides enhanced distribution of NH-3 to the 
CNS while minimizing T3 antagonism in the periphery.60 
In conclusion, we have found that TREM2 is a direct target gene of thyroid hormone, 
making TREM2 and its signaling pathway in macrophages and microglia subject to regulation by 
a major endocrine system. To our knowledge ours is the first report of endogenous regulation of 
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TREM2 at the level of gene expression, and it is likely to have important physiological and 
pathophysiological ramifications for TREM2-mediated innate immunity. This finding also 
represents a path toward developing small molecule therapeutics that either activate or 
suppress the TREM2 signaling pathway selectively in the CNS or periphery. The ability to “drug” 
TREM2 and its pathway with small molecule agents possessing good, drug-like properties 
would be an important medical advance for the diverse collection of diseases that intersect with 
TREM2 biology. 
Methods 
Reagents. T3 was purchased and used as received from Sigma-Aldrich. Sobetirome, Sob-AM2, 
and NH-3 were prepared as described in the literature.14, 61-62 Vehicle and drug stocks for cell 
culture experiments were prepared in dimethyl sulfoxide (DMSO). For in vivo experiments, all 
drugs were prepared at concentrations suitable for an i.p. injection of 150 μL per 26-g mouse. 
T3 drug stocks were prepared in 8 mM NaOH in saline and sobetirome and Sob-AM2 drug 
stocks were prepared in 50% DMSO in saline solutions. Vehicle stock solutions of 50% DMSO 
in saline (vehicle for sobetirome and Sob-AM2) or 8 mM NaOH in saline (T3 vehicle) were 
prepared and administered within the appropriate experiments. Drug concentrations are 
described in the figure legends for individual experiments. SARS-CoV-2 S1 protein was 
purchased from ACROBiosystems (#S1N-C52H3) and used as received. Information on other 
specific reagents is listed below within the Methods description for that particular experiment.  
Study approval and animals. All experiments were approved by the IACUC committee at the VA 
Portland Health Care System (VAPORHCS) or OHSU. Wild-type C57BL/6 mice, aged 8 to 10 
weeks, were purchased from Jackson Laboratory and housed in climate-controlled rooms with a 
12-hour light/12-hour dark cycle with ad libitum access to food and water. Mice were made 
hypothyroid by receiving 0.1% (w/v) methimazole and 0.2% (w/v) potassium perchlorate 
(Sigma-Aldrich) in drinking water for 2 weeks.63  
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Cell culture. Mouse (ScienCell, #M1900-57) and human primary (Celprogen, #37089-01) 
microglia cells were purchased from and cultured according to the manufacturer’s protocol. 
RAW 264.7 cells were purchased fromm ATCC (ATCC® TIB-71™) and cultured according to the 
manufacturer’s protocol in DMEM containing 10% FBS. Mouse primary lung macrophages were 
purchased from CellBiologics (#C57-2313F) and cultured according to the manufacturer’s 
protocol in DMEM containing 10% FBS. All cells were incubated at 37°C in the presence of 5% 
CO2. For experiments, cells were plated in either 6, 12, or 24 well plates at ~2 x 10
5 cells per 
well.  
RT-qPCR. All cell cultures were serum-starved for 24 h before drug treatment, then treated with 
either DMSO vehicle, 10 nM T3, 1 μM sobetirome, or 2 μM NH-3 in the presence of 10 nM T3 
for 24 h before RNA extraction. For mouse whole brain data, male C57Bl/6 mice (8-10 weeks 
old) were made hypothyroid according to standard procedure.63 Mouse cohorts were 
administered DMSO vehicle, 3.05 μmol/kg T3, or 30.5 μmol/kg Sob-AM2 and euthanized 6 h 
post-injection. Brains were immediately stored in 10-fold excess RNALater (Thermo Fisher) for 
RNA preservation. RNA was purified using either the RNeasy Mini Kit (Qiagen) or the PureLink 
RNA Mini kit with TRIzol extractions (Life Technologies) and quantified using a NanoDrop. PCR 
reactions were run on 1 μg of RNA per sample to afford cDNA using the QuantiTect Reverse 
Transcription kit (Qiagen). RT-qPCR was performed on an Applied Biosciences 7500 Real-Time 
PCR system following the QuantiTect SYBR Green PCR kit protocols (Qiagen) using 
Cyclophilin A (Ppia) and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as 
housekeeping genes for mouse and human samples, respectively. Samples were run with 
technical duplicates and results were analyzed using the ΔΔCt relative quantification method.64  
Mouse primers: f-Ppia 5′-AGGGTGGTGACTTTACACGC-3′, r-Ppia 5′-
CTTGCCATCCAGCCATTCAG-3′; f-Trem2 5’-GACCTCTCCACCAGTTTCTCC-3’, r-Trem2 5’-
TACATGACACCCTCAAGGACTG-3’; f-Cd68 5’-TTCTGCTGTGGAAATGCAAG-3’, r-Cd68 5’-
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GAGAAACATGGCCCGAAGT-3’; f-Il1b 5′-TCCAGGATGAGGACATGAGCAC-3′, r-Il1b 5′-
GAACGTCACACACCAGCAGGTTA-3′, f-Il6 5’-GTTGCCTTCTTGGGACTGATG-3’, r-Il6 5’-
CATACAATCAGAATTGCCATTGC-3’.54, 65-68 
Human primers: f-GAPDH 5’-CAGGAGGCATTGCTGATGAT-3’, r-GAPDH 5’-
GAAGGCTGGGGCTCATTT-3’; f-TREM2 5’-ACAGAAGCCAGGGACACATC-3’, r-TREM2 5’-
CCTCCCATCATCTTCCTTCA-3’.69-70 
Phagocytosis assay and immunocytochemistry. Mouse primary microglia cells were plated onto 
poly-L-lysine coated glass coverslips at ~5 x 104 cells per coverslip seated within a 12 well plate 
(3 coverslips per group, 4 groups total). Cells were treated with DMSO vehicle, 10 nM T3, 1 μM 
sobetirome, or 2 μM NH-3 in the presence of 10 nM T3 for 24 h before the addition of 3 μL of a 
fluorescent latex bead suspension (L0280, Sigma) in complete DMEM in a ~100:1 bead-to-cell 
ratio for 2 h before the end of the experiment. Each well was then stripped of media, washed 
with PBS, and cells were fixed with 4% paraformaldehyde in PBS for 10 min at room 
temperature. The cells were then permeabilized with PBS containing 0.05% saponin (saponin 
was included in all subsequent incubations and washes) and stained for microglial marker 
CD11b using monoclonal rat anti-mouse CD11b (1:200 dilution, AbD Serotec, #MCA711) in 
conjunction with Alexa Fluor 488-conjugated donkey anti-mouse secondary antibody (1:400 
dilution,Thermo Fisher, A21202). Coverslips were then washed and mounted with ProLong® 
Gold antifade reagent (Life Technologies). Two fields per coverslip were imaged for a total of six 
fields of microglial cells per group imaged with a Zeiss ApoTome.2 at 20x magnification 
collecting z-stack images to verify the entrapment of fluorescent beads within the CD11b-
stained cell field. Images were acquired and processed with ZEN 2 (blue edition) version 3.1 
software (Zeiss), ImageJ/FIJI, and IMARIS software (Bitplane). Blue fluorescent beads were 
colorized to red during image post-processing in IMARIS for ease of visualization.                            
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EAE experiment, histology, and immunofluorescence. Immunization of female C57BL/6 mice 
(The Jackson Laboratory, Bar Harbor, ME, ages 8-10 weeks) with 200 µg of myelin 
oligodendrocyte glycoprotein (MOG) 35-55 (PolyPeptide Laboratories, San Diego, CA) in 
complete Freund’s adjuvant containing 400 µg of Mycobacterium tuberculosis per mouse 
(subcutaneous injection of 0.2ml volume), followed by pertussis toxin (List Biological labs Inc), 
was administered via intraperitoneal (i.p.) injection at day 0 (75ng per mouse) and day 2 (200ng 
per mouse) after immunization. All mice were scored for clinical signs of EAE daily using a 9-
point scale and received one-time daily i.p. injections of vehicle (50% DMSO or 8mM NaOH, 
both in saline) or drug (T3 0.4 mg/kg or Sob-AM2 1 mg/kg) starting at day 7 through euthanasia 
on day 21 post-immunization. Each group contained 6-8 mice and the experiment was repeated 
3 times. At 21 days post-immunization, mice were euthanized with carbon dioxide and spinal 
columns were removed. Columns were immersed in 4% paraformaldehyde (PFA) for 24-48 
hours, then spinal cords were extracted and fixed in a microwave for 1 hour. Free-floating 40 μm 
lateral sections were collected from the lumbar region using a vibratome, then stored in PBS at 
4°C. Tissues were permeabilized with 0.05% Triton X-100 in PBS for 30 minutes, washed in 
PBS, then blocked with 5% donkey serum in PBS for 3 hours. Sections were incubated in 
primary monoclonal anti-TREM2 antibody (EMD Millore, MABN2320, 1:250) in blocking buffer 
overnight at 4°C. Tissues were washed in PBS, then incubated in Alexa Fluor 647-conjugated 
goat anti-rat secondary antibody (Thermo Fisher, A21247, 1:200) and DAPI (1:50000) in PBS 
overnight at 4°C. Sections were washed and mounted on slides using ProLong® Gold antifade 
reagent (Life Technologies) and imaged using Zeiss 780 laser scanning confocal microscope at 
20x. Cells expressing TREM2 were quantified within the region of dorsal white matter. Images 
were acquired and processed with ZEN 2 (blue edition) version 3.1 software (Zeiss), 
ImageJ/FIJI, and IMARIS software (Bitplane). TREM2 was colorized white in ImageJ/FIJI during 
post-processing for ease of visualization. Quantification of TREM2 concentration via ELISA was 
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performed using a TREM2 ELISA kit (Reddot Biotech Inc). following the manufacturer’s 
instructions.  
Statistical analysis. Statistical significance was determined using 1-way ANOVA with Dunnett’s 
post-test or two-tailed, unpaired Student’s t tests between two groups and then plotted together 
graphically as denoted in each figure legend (P < 0.05). For in vivo experiments, there were no 
differences in effects between the different vehicles (8 mM NaOH in saline or 50% DMSO in 
saline), so data from the different vehicles were combined into a single vehicle control group. 
Replicates for each experiment were as stated in the specific figure legend and in the 
corresponding methods. Sample sizes for animal experiments were informed by previous 
literature accounts or from preliminary data to minimize total animal numbers as appropriate. 
Analysis was carried out in GraphPad Prism 8 without further modifications. The ROUT method 
was used to identify and eliminate outliers. Significance level was set to *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001, and ****P ≤ 0.0001. All graphs show mean ± SEM. 
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Figure 1: RXR-TR heterodimer associated with a DR4-TRE located in the promoter region of 
TREM2 (a, PDB ID: 2NLL and 4ZO1) and endogenous and synthetic TR ligands used in this 
study (b).  
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Figure 2: RT-qPCR demonstrating that T3 and thyromimetics regulate TREM2 expression in 
vitro and in vivo. TR agonists T3 (10 nM) and sobetirome (1 μM) upregulate TREM2 in mouse 
(a) and human (b) primary microglia, (c) mouse macrophage cell line RAW 264.7, (d) 
hypothyroid mouse whole brain extract (3.05 μmol/kg T3 and 30.5 μmol/kg Sob-AM2), and alter 
the transcript levels of TREM2 pathway-connected genes by upregulating (e) Cd68 and 
downregulating (f) Il1b in mouse primary microglia (n = 3-5 as denoted). In contrast, TR 
antagonist NH-3 (2 μM NH-3 with 10 nM T3) downregulated Trem2 (a) and Cd68 (e) in mouse 
primary microglia. Statistical significance was determined by a 2-tailed, unpaired t test for 
comparisons between vehicle and group then were plotted together. Asterisks represent 
significant difference from vehicle unless otherwise noted (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001). 












(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprintthis version posted January 27, 2021. ; https://doi.org/10.1101/2021.01.25.428149doi: bioRxiv preprint 
29
 
Figure 3: RT-qPCR of mouse RAW264.7 macrophage cells (a) and mouse primary lung 
macrophages (b-d) stimulated with 10 μg/mL SARS-CoV-2 S1 protein with and without 
treatment with 10 nM T3 (n = 5-7 as denoted). T3 treatment suppresses pro-inflammatory 
cytokine expression (Il6 and Il1b, a-c) and upregulates Trem2 expression following inflammatory
stimulation  with the S1 protein(d). Statistical significance was determined by a 2-tailed, 
unpaired t test for comparisons between vehicle and group then were plotted together. Asterisks 
represent significant difference from vehicle unless otherwise noted (*P ≤ 0.05, **P ≤ 0.01, 
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Figure 4: T3 stimulates and NH-3 blocks phagocytosis by microglia. C57BL/6 mouse primary 
microglia cells in culture were treated with DMSO vehicle (a + a’), 10 nM T3 (b + b’), 1 μM 
sobetirome (c + c’), or 2 μM NH-3 (d + d’) for 24 h before 2 μm diameter fluorescent beads 
(~100/cell) were introduced 2 h before cells were fixed and stained for Cd11b (green). (e) 
Elongated morphology of an unactivated/ramified microglia cell. (f) Morphology of an activated 
microglia cell upon treatment with sobetirome (see supporting information). (g) Three-
dimensional view of beads inside the uppermost cell in the sobetirome treatment group (image 
generated in Imaris). (h) Quantification of phagocytosed beads per treatment group. Scale bars 
are 20 μm (a-d), 10-20 μm (a’-d’), and 8-10 μm (e-g) as noted. Statistical significance was 
determined by a 2-tailed, unpaired t test for comparisons between vehicle and group then were 
plotted together. Asterisks represent significant difference from vehicle unless otherwise noted 
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Figure 5: Treatment of EAE mice with T3 and Sob-AM2 upregulates TREM2 expression in 
diseased spinal cord regions. (a-c) EAE mice were treated with vehicle, T3 (0.4 mg/kg), or Sob-
AM2 (1 mg/kg) i.p. for 15 days (day 7-21). (a-c) Representative immunofluorescence images 
showing TREM2 protein expression within the dorsal white matter in the lumbar section of spinal
cord. Scale bars: 100 μm. (d) Cells expressing TREM2 (white) within the dorsal white matter 
were quantified. T3 and Sob-AM2 increased TREM2 expression four-fold and three-fold 
compared to vehicle, respectively. Data represents images from vehicle (n = 18), T3 (n = 12), 
and Sob-AM2 (n = 12). Two sections were used from each mouse. Significance was determined 
using one-way ANOVA (P < 0.05). (e) ELISA measurement of TREM2 in spinal cord extracts 
from the same cohorts of EAE mice (n = 3) used in a-d. (f) Daily EAE clinical disease scores 
from vehicle (n = 18), T3 (0.4 mg/kg, n = 15), and Sob-AM2 (1 mg/kg, n = 28) treated cohorts. 
Statistical significance was determined by a two-tailed, unpaired t test comparing vehicle and 
treatment group per day with each t test performed independently. Asterisks represent 
significant difference from vehicle unless otherwise noted. (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001). 
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